Quantitative Measurement of the SARS-CoV-2 IgG Antibody and Surrogate Neutralizing Antibody Responses among mRNA COVID-19 Vaccine-Inoculated Medical Staff in Designated Medical Institutions for Infectious Diseases

Kansenshogaku Zasshi Pub Date : 2022-03-20 DOI:10.11150/kansenshogakuzasshi.96.52

Shintaro Nagashima, Yoshihiro Kitahara, Aya Sugiyama, Mafumi Okimoto, Bunthen E, Serge Ouoba, Ko Ko, T. Takafuta, J. Tanaka

{"title":"Quantitative Measurement of the SARS-CoV-2 IgG Antibody and Surrogate Neutralizing Antibody Responses among mRNA COVID-19 Vaccine-Inoculated Medical Staff in Designated Medical Institutions for Infectious Diseases","authors":"Shintaro Nagashima, Yoshihiro Kitahara, Aya Sugiyama, Mafumi Okimoto, Bunthen E, Serge Ouoba, Ko Ko, T. Takafuta, J. Tanaka","doi":"10.11150/kansenshogakuzasshi.96.52","DOIUrl":null,"url":null,"abstract":"This study was aimed at evaluating the changes in the antibody titers and neutralization ability before and after inoculation with an mRNA COVID-19 vaccine (Pfizer, USA) among healthcare professionals (HCPs) in Japan. A total of 221 HCPs were enrolled and their blood samples were collected at three time points: (1) before vaccination, (2) 3 weeks after the first dose, and (3) 3 weeks after the second dose. The titers of anti-SARS-CoV-2 Spike protein IgG antibody were measured in all the samples using VITROS-Anti-SARS-CoV-2 S1 Quant IgG Antibody (CLEIA, Ortho-Clinical Diagnostics, Inc.), and the surrogate Virus Neutralization Test (sVNT) (ELISA, GenScript, USA) was performed in the samples obtained after the vaccination. The anti-SARS-CoV-2 IgG titers were (1) median: 0.16;Interquartile (IQR): 0.10-0.27, (2) median: 250;IQR: 99.5-466 and (3) median: 2,400;IQR: 1,480-3,950, respectively, at the three time-points. Our study also revealed the relationship between the anti-SARS-CoV-2 IgG antibody titer and the antibody neutralization activity.","PeriodicalId":17713,"journal":{"name":"Kansenshogaku Zasshi","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kansenshogaku Zasshi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11150/kansenshogakuzasshi.96.52","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

This study was aimed at evaluating the changes in the antibody titers and neutralization ability before and after inoculation with an mRNA COVID-19 vaccine (Pfizer, USA) among healthcare professionals (HCPs) in Japan. A total of 221 HCPs were enrolled and their blood samples were collected at three time points: (1) before vaccination, (2) 3 weeks after the first dose, and (3) 3 weeks after the second dose. The titers of anti-SARS-CoV-2 Spike protein IgG antibody were measured in all the samples using VITROS-Anti-SARS-CoV-2 S1 Quant IgG Antibody (CLEIA, Ortho-Clinical Diagnostics, Inc.), and the surrogate Virus Neutralization Test (sVNT) (ELISA, GenScript, USA) was performed in the samples obtained after the vaccination. The anti-SARS-CoV-2 IgG titers were (1) median: 0.16;Interquartile (IQR): 0.10-0.27, (2) median: 250;IQR: 99.5-466 and (3) median: 2,400;IQR: 1,480-3,950, respectively, at the three time-points. Our study also revealed the relationship between the anti-SARS-CoV-2 IgG antibody titer and the antibody neutralization activity.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

传染病定点医疗机构接种mRNA - COVID-19疫苗医务人员SARS-CoV-2 IgG抗体和替代中和抗体反应的定量测定

本研究旨在评估接种mRNA COVID-19疫苗(美国辉瑞公司)前后日本医护人员(HCPs)抗体滴度和中和能力的变化。共纳入221名HCPs，并在三个时间点采集血样:(1)接种前，(2)第一次接种后3周，(3)第二次接种后3周。所有样品均采用VITROS-Anti-SARS-CoV-2 S1 Quant IgG antibody (CLEIA, Ortho-Clinical Diagnostics, Inc.)检测抗sars - cov -2刺突蛋白IgG抗体滴度，接种后样品采用替代病毒中和试验(sVNT) (ELISA, GenScript, USA)检测。三个时间点的抗sars - cov -2 IgG滴度分别为(1)中位数:0.16，四分位数(IQR): 0.10-0.27，(2)中位数:250,IQR: 99.5-466，(3)中位数:2400,IQR: 1480 - 3950。我们的研究还揭示了抗sars - cov -2 IgG抗体滴度与抗体中和活性之间的关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Kansenshogaku Zasshi

自引率

0.00%

发文量